Draxis Health Starts Phase III Fibrimage Trials MISSISSAUGA, Ont. -- Draxis Health Inc. (DRAX) said its Draximage Inc. radiopharmaceutical subsidiary has started Phase III clinical trials in Canada for Fibrimage, a diagnostic tool for deep vein thrombosis, or DVT. In a news release, the drug company said the trial should involve 130 patients and be completed by the end of the year. DVTs are blood clots that form in the lower limbs and can lead to a pulmonary embolism, or a blockage of blood flow to the lungs, a condition that kills about 200,000 people a year in the U.S., it said. It said Fibrimage is based on Fibrin Binding Domain, a recombinant polypeptide developed by Bio-Technology General Corp.
(BTGC) and licensed to Draximage on an exclusive, worldwide basis